Greg Longmore Headshot

Professor of Medicine (Oncology), Cell Biology & Physiology
Director, ICCE Institute
Washington University, St. Louis


Greg Longmore is currently Professor of Medicine and Cell Biology at Washington University School of Medicine in St. Louis.  He is the director of the ICCE Institute, a multidisciplinary cancer research center dedicated to understanding tumor-environment communication during cancer progression; co-director of the Molecular Oncology section of the division of Oncology in the Department of Medicine; and co-director of the basic science research program of the Siteman Cancer Center at Washington University.  He received his BSc. degree in Chemistry from the U. Western Ontario. After graduate work in Biochemistry from the U. Toronto he completed a medical degree from McGill University in Montreal.  Following medical school, he completed Internal Medicine and Medical Oncology clinical training at Harvard Medical School, and then did postdoctoral research studies in Cell Biology at the Whitehead Institute, MIT.  Prior to joining the faculty at Washington University he held a faculty position at Harvard Medical School.  He has published over 100 peer-reviewed publications in respected journals, been invited to present lectures at many national and international meetings and an invited lecturer at Universities within the US, Canada, Europe, and Asia.  He has been a member of multiple National Institutes for Health and American Cancer Society grant review panels, chairing at least three of these panels and is currently a member of the Council for extramural grants at the American Cancer Society.  Longmore has been on the editorial boards for Cancer Research, Molecular and Cellular Biology, Molecular Cancer Research, Faculty of 1000 (Cell and Developmental Biology), and BMC Biology.  He has also been an external advisor/consultant for research programs and departments at a number of cancer centers, universities, as well as pharma companies. The Longmore laboratory major research focus is to determine how tumor cells and their immediate environment communicate with one another to facilitate tumor cell invasion and metastasis.  His laboratory has identified a number of novel pathways and therapeutic targets, how they work, and is developing novel therapeutic interventions that selectively target these pathways so as to prevent or abrogate cancer metastasis.